Found 25 articles for: "Melasma"
A Novel Topical Agent for the Management of Hyperpigmentation, Including Melasma and Age Spots
January 2026 | Volume 25 | Issue 1 | Original Article | 75 | Copyright © January 2026
Background/Objectives: Melasma and age spots are among the most persistent and difficult-to-treat forms of hyperpigmentation. While traditional therapies offer some clinical effi...
Read MoreEvaluation of an Advanced, Multimodal Skin Tone Correcting Serum in Participants With Mild-to-Severe Dyschromia and Hyperpigmentation
January 2026 | Volume 25 | Issue 1 | Original Article | 36 | Copyright © January 2026
Background: A new multimodal skin tone correcting serum formulated with b.r.y.t.e.r. (brown, red, and yellow tones with enhanced resurfacing) technology (EV-I) targets brown, red...
Read MoreA Randomized, Controlled, Split-Face, Double-Blind Study Comparing Topical Malassezin to Hydroquinone 4% for Melasma
January 2026 | Volume 25 | Issue 1 | Original Article | 25 | Copyright © January 2026
Background: Previous studies have documented the capacity of malassezin to brighten the skin. It represents a novel agent for the treatment of hyperpigmentation.Clinical Evaluation of Thiamidol-Containing Formulations for the Visual Management of Facial Hyperpigmentation
December 2025 | Volume 24 | Issue 12 | Original Article | 1195 | Copyright © December 2025
Read MorePhotoprotection Efficacy of Sun Protection Factor and Iron Oxide Formulations in Diverse Skin With Melasma and Photodamage
July 2025 | Volume 24 | Issue 7 | Original Article | 662 | Copyright © July 2025
Visible light (400-700nm) comprises 45% of the sunlight spectrum and can induce both immediate and persistent skin darkening, as well as worsen dyschromia, especially in the skin of color populat...
Read MoreThiamidol: A Breakthrough Innovation in the Treatment of Hyperpigmentation
June 2025 | Volume 24 | Issue 6 | Original Article | 608 | Copyright © June 2025
Cutaneous hyperpigmentation, including melasma, solar lentigines, and post-inflammatory hyperpigmentation (PIH), results in a significant impact on patients’ quality of life. Unfortunately,...
Read MoreGender, Racial, and Fitzpatrick Skin Type Representation in Melasma Clinical Trials
January 2025 | Volume 24 | Issue 1 | Original Article | 19 | Copyright © January 2025
Melasma, a symmetric pigmentary disorder, is more prevalent in women and individuals with darker skin tones. Despite its global prevalence, there is a notable gap in the understanding of gender, ...
Read MoreThe Burden of Melasma: Race, Ethnicity, and Comorbidities
August 2024 | Volume 23 | Issue 8 | Features | 691 | Copyright © August 2024
Introduction: In an effort to define the characteristics of populations affected by melasma, we utilized a large global health research network database from 108 health care orga...
Read MoreRepresentation of Skin of Color in Social Media Discussions on Melasma, Keloids, and Vitiligo
July 2024 | Volume 23 | Issue 7 | Original Article | 510 | Copyright © July 2024
Background: The prevalence of social media as a source of medical information has grown substantially in recent years, especially for skin conditions disproportionately affecting...
Read MoreEfficacy, Safety, Satisfaction, Adherence to Treatment With Nano-Formulated Cysteamine Tranexamic Acid Cream to Treat Melasma
July 2024 | Volume 23 | Issue 7 | Original Article | 529 | Copyright © July 2024
Background: Melasma is a chronic pigmentary disorder. In this study, an innovative cream combining cysteamine and tranexamic acid (TXA) was assessed.Objectiv...
Read MoreExpanding Inclusivity: Tranexamic Acid for the Treatment of Melasma in Males
April 2024 | Volume 23 | Issue 4 | Editorials | e110 | Copyright © April 2024
Cysteamine Isobionic-Amide Complex Versus Kligman's Formula for the Treatment of Melasma: Equal Efficacy and Rapid Onset of Action
February 2024 | Volume 23 | Issue 2 | Original Article | 9 | Copyright © February 2024
Background: Modified Kligman's formula (mKF) is the gold standard treatment for melasma; however, its prolonged use is not recommended due to side effects. Cysteamine is a potent...
Read MoreTopical Treatments for Melasma and Post-inflammatory Hyperpigmentation
November 2023 | Volume 22 | Issue 11 | Original Article | 1118 | Copyright © November 2023
Background: Dyschromia is one of the most common reasons for patients to seek dermatological care, especially among individuals with skin of color. Most cases present as melasma ...
Read MoreOptimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus
April 2023 | Volume 22 | Issue 4 | Original Article | 386 | Copyright © April 2023
Because of its complex pathogenesis, chronicity, and high rates of recurrence, melasma is regarded as a challenging skin disorder. Topical treatments are often offered as first-line therapy. Howe...
Read MoreA Randomized, Double-Blind, Split-Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas
December 2022 | Volume 21 | Issue 12 | Original Article | 1304 | Copyright © December 2022
Background: Hydroquinone is effective in melasma treatment, but side effects may limit its use. Silymarin cream may be a safer alternative. Objective: To compare the ...
Read MoreOral Tranexamic Acid for the Treatment of Melasma: A Case Series and Novel Dosing Regimen
April 2022 | Volume 21 | Issue 4 | Original Article | 393 | Copyright © April 2022
Melasma is a common disorder affecting millions of people around the world.1 It is a condition that can disrupt one’s self-esteem and overall quality of life.2 Melasma is c...
Read MoreA Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma
March 2022 | Volume 21 | Issue 3 | Editorials | 321 | Copyright © March 2022
Oral tranexamic acid (TXA) is a relatively new treatment option for melasma. It is thought to reduce hyperpigmentation through inhibition of the plasminogen/plasmin pathway with resulting decreases in...
Read MoreSuccessful Management of a Black Male With Psoriasis and Dyspigmentation Treated With Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion: Case Report
October 2020 | Volume 19 | Issue 10 | Case Reports | 1000 | Copyright © October 2020
Skin of color patients with psoriasis face unique challenges related to disease characteristics and treatment. Dyspigmentation, including postinflammatory hypo- and hyperpigmentation, more frequently ...
Read MoreMelasma’s Impact on Quality of Life
February 2020 | Volume 19 | Issue 2 | Original Article | 184 | Copyright © February 2020
Melasma is a commonly acquired condition that mostly affects women with Fitzpatrick skin types III-VI with prominent brown pigmentation with or without an underlying erythema. Despite multiple treatme...
Read MoreTopical Treatments for Melasma: A Systematic Review of Randomized Controlled Trials
November 2019 | Volume 18 | Issue 11 | Original Article | 1156 | Copyright © November 2019
Background: Melasma is an acquired skin disease characterized by symmetric hyperpigmentatio...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
